article · Universal Journal of Pharmaceutical Research
The immune systems of children that are still developing are particularly susceptible to being affected by long-lasting infections like HIV. Children infected perinatally show indications of immune aging or immune senescence significantly sooner than their uninfected counterparts, even with the prompt start of combination antiretroviral therapy (cART). This rapid aging process is marked by persistent immune activation, thymic impairment, disrupted hematopoiesis, and the premature buildup of senescent and weary immune cells. These changes jeopardize immune function during a vital period of growth and development. At the heart of HIV-related senescence in children is the ongoing condition of systemic inflammation and immune imbalance, despite the presence of viral suppression. Thymic involution diminishes the production of naïve T-cells, whereas telomere shortening and increased levels of senescence markers like p16^INK4a and PD-1 indicate cellular tiredness. These immunological changes have significant clinical consequences, including heightened vulnerability to infections, insufficient vaccine efficacy, and premature development of non-AIDS-related comorbidities like cardiovascular and neurocognitive issues. Peer Review History: Received 6 December 2025; Reviewed 11 January 2026; Accepted 13 February; Available online 15 March 2026 Academic Editor: Dr. Sally A. El-Zahaby, Pharos University in Alexandria, Egypt, sally.elzahaby@yahoo.com Reviewers: Dr. Sabah Hussien El-Ghaiesh, Tanta University, Egypt, s.ghaiesh@gmail.com Dr. Sameh Abdelmoneem Mohammed Ali, Faculty of Pharmacy, Beni-Suef University, Egypt, same7_pharma18@yahoo.com
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.22270/ujpr.v11i1.1491
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.